BioCentury | Oct 21, 2020

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

...that is in a Phase II trial to treat pulmonary infections and complications, as well as SNSP003...
...the convalescent patient-derived mAb reduced lung and nasal virus levels and signs of lung pathology. BC Staff NYX-783 SNSP003 SNSP113 Aridis...
Items per page:
1 - 1 of 1